

Occludin: Structure, function and regulation

Gemma J. Feldman^a, James M. Mullin^b, Michael P. Ryan^{a,*}

^a*Department of Pharmacology, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland*

^b*Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096-411, USA*

Received 25 June 2004; accepted 4 January 2005

Available online 9 March 2005

Abstract

Epithelial and/or endothelial barriers play a critical role in animal, including human, life forms. The tight junction (TJ) is an essential component of these barriers. Occludin is a major component of the TJ. The structure of occludin, including its gene splice variants and protein essential components have been elucidated.

Phosphorylation/dephosphorylation plays a major role in regulation of occludin and TJ. Disruption of occludin regulation is an important aspect of a number of diseases. Strategies to prevent and/or reverse occludin downregulation may be an important therapeutic target.

© 2005 Published by Elsevier B.V.

Keywords: Occludin; Tight junction; ZO-1; Claudin; Phosphorylation; GTPases; Proteases; Cytokines; Cancer; Inflammatory diseases

Contents

1. Introduction and discovery	885
2. Occludin structure and binding partners	888

Abbreviations: TJ, tight junction; ZO, zonula occludens; mAb, monoclonal antibody; BRB, blood–retinal barrier; TER, transepithelial/endothelial electrical resistance; IPTG, isopropyl-β-D-thiogalactoside; RT-PCR, reverse transcription-polymerase chain reaction; bp, base pair; TM4, fourth transmembrane domain; MAGUK, membrane-associated guanylate kinase; CTX, cortical thymocyte marker in *Xenopus*; CLMP, coxsackie- and adenovirus receptor-like membrane protein; LC, low calcium; NC, normal calcium; MW, molecular weight; LMW, low molecular weight; HMW, high molecular weight; CBDL, common bile duct ligation; BBB, blood–brain barrier; CNS, central nervous system; IFN, interferon; PKC, protein kinase C; PMA, phorbol-12-myristate-13-acetate; Ca²⁺, calcium; MAPK, mitogen-activated protein kinase; PP2A, protein phosphatase 2A; BBB, blood–brain barrier; PLC, phospholipase C; MMP, matrix metalloproteinase; PAO, phenylarsine oxide; PV, pervanadate; PI, phosphatidylinositol; EPEC, enteropathogenic *Escherichia coli*; CK, casein kinase; PKA, protein kinase A; HDM, house dust mite; TGF, transforming growth factor; IL, interleukin; HGF, hepatocyte growth factor; EMT, epithelial–mesenchymal transition.

* Corresponding author. Tel.: +353 1 7166738; fax: +353 1 2692749.

E-mail address: michael.p.ryan@ucd.ie (M.P. Ryan).

2.1.	The unique roles of specific occludin domains	888
2.1.1.	COOH-terminus	888
2.1.2.	N-terminus	888
2.1.3.	Extracellular and transmembrane domains	889
2.1.4.	Coiled-coil domain of COOH-terminal region	890
2.1.5.	Sequence variations between species.	890
2.1.6.	Occludin gene and splice variants	890
2.2.	Occludin's binding partners	891
2.2.1.	ZO-1, ZO-2, ZO-3	891
2.2.2.	Junctional adhesion molecule	891
2.2.3.	VAP-33.	891
2.2.4.	JEAP	892
2.2.5.	CLMP	892
3.	Regulation of occludin by phosphorylation	892
3.1.	Serine/threonine phosphorylation	893
3.2.	Tyrosine phosphorylation of occludin.	895
3.3.	The identification of occludin kinases.	896
4.	Other regulatory mechanisms	897
4.1.	Regulation by small GTPases.	897
4.2.	Regulation by proteases.	898
4.3.	Regulation by cytokines.	899
4.4.	Regulation by miscellaneous factors	900
4.4.1.	Understanding the regulation of occludin	900
5.	Occludin: principal component or merely a building block?	900
5.1.	Occludin and drug delivery: the way in?	902
6.	Occludin expression in different cell and tissue types.	902
6.1.	Salivary glands	902
6.2.	Sertoli cells	902
6.3.	Renal cells	903
6.4.	Skin	903
6.5.	Oesophagus	904
6.6.	Corneal epithelium	904
6.7.	Bladder epithelium	904
6.8.	Liver	905
6.9.	Dentition	905
6.10.	Major blood vessel endothelium	905
6.11.	Blood–brain barrier	905
6.12.	Blood–retinal barrier	906
7.	Occludin and disease—the way asunder.	906
7.1.	Diarrhoea	906
7.2.	Cancer.	907
7.3.	Inflammation	907
7.4.	Allergies.	908
7.5.	Diabetes	908
7.6.	Miscellaneous diseases	909
7.7.	Therapeutic approaches	909
8.	Conclusion.	909
	References	909

Download English Version:

<https://daneshyari.com/en/article/10883835>

Download Persian Version:

<https://daneshyari.com/article/10883835>

[Daneshyari.com](https://daneshyari.com)